Costly Utterances
OPINION: A costly out-of-court settlement has hit dual-listed processor a2 Milk Company.
The US Food and Drug Administration (FDA) told A2 that it is deferring further consideration of the company's request to export its infant-formula products into the US.
The US produces almost all of its own baby formula for domestic consumption, but the market is dominated by a few top players. That's led to some distressing shortages over the past few months, which has investors wondering if A2 Milk shares could receive some helpful tailwinds.
While A2 Milk (and even Fonterra) has yet to step in to help fill the void, some other international companies, like European based Danone, have tripled their exports to the States in recent months.
